Search FBIO
Fortress Biotech, Inc.
Nasdaq, Nasdaq · CIK 1429260
Last close2.03
Daily change-0.04 (-1.93%)
10 Years gain-95.50%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
FBIO · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
44.7Momentum
n/aAcceleration
n/aConfidence
69.0Annual Revenue13
Quarterly Revenue50
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth7.1 / 25
Quality20.4 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Heavy share dilution · HIGHDiluted share count increased 20.1925%.
Key Metrics
Revenue Growth TTM23.53%OK
Revenue CAGR 3Y-5.83%OK
Gross Margin66.49%OK
Operating Margin-88.7%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y20.19%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $63.26M | $42.34M | -$70.22M | -$65.78M | n/a | 66.92% | -111% | n/a | -239.4% | 27.9M |
| 2025 FY Dec 31, 2024 | $57.68M | $36.80M | -$110.38M | -$80.19M | n/a | 63.8% | -191.38% | n/a | -673.12% | 20.78M |
| 2024 FY Dec 31, 2023 | $84.51M | $61.62M | -$142.34M | -$128.23M | -$128.29M | 72.91% | -168.43% | -151.8% | n/a | 8.11M |
| 2023 FY Dec 31, 2022 | $75.74M | $44.97M | -$203.56M | -$179.40M | -$182.12M | 59.37% | -268.76% | -240.44% | n/a | 5.92M |
| 2022 FY Dec 31, 2021 | $68.79M | $36.71M | -$188.54M | -$116.54M | -$121.11M | 53.36% | -274.08% | -176.05% | n/a | 81.7M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $68.80M | sum latest 4 fiscal quarters Revenue | OK | 0001104659-26-095964, 0001104659-25-111989 |
| Revenue Growth TTM | 23.53% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001104659-26-095964, 0001104659-25-111989 |
| Revenue CAGR 3Y | -5.83% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-037874 |
| Revenue CAGR 5Y | 6.77% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-037874 |
| Gross Profit CAGR 3Y | -1.99% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-037874 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001104659-26-095964, 0001104659-25-111989 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 66.49% | Gross Profit / Revenue | OK | 0001104659-26-095964, 0001104659-25-111989 |
| Operating Margin | -88.7% | Operating Income / Revenue | OK | 0001104659-26-095964, 0001104659-25-111989 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001104659-26-095964 |
| Current Ratio | 3.96x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 5.62x | (Cash + Short-term Investments) / Total Debt | OK | 0001104659-26-095964 |
| Revenue per Diluted Share | $2.16 | Revenue / Diluted Shares | OK | 0001104659-26-095964, 0001104659-25-111989 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |